Pharma firms pile pressure on the UK as Trump's drug pricing order looms

Major pharmaceutical firms, including AstraZeneca, Merck, and Eli Lilly, have paused or withdrawn over £1.2 billion in U.K. investments, citing a lack of competitive drug pricing and government support. This coordinated pressure, coinciding with a U.S. deadline for drug price commitments, is seen by analysts as a negotiating tactic to secure better terms from the U.K., which has seen its foreign direct investment in the pharma sector decline significantly. The trend reflects a broader industry shift towards reallocating capital to the U.S. due to incentives, positioning the U.K. as an early casualty and potentially signaling future challenges for other European economies.

Analysis

Major pharmaceutical firms, including AstraZeneca (AZN), Merck (MRK), and Eli Lilly (LLY), are applying significant pressure on the U.K. government by halting or withdrawing over £1.2 billion in planned investments. The companies cite an uncompetitive landscape and the "undervaluation" of innovative medicines, a claim substantiated by the recent collapse of drug pricing negotiations. However, analysts suggest this is a coordinated negotiating tactic timed to coincide with a looming September 29 deadline for the U.S. administration's 'most favored nation' drug pricing order. This U.S. policy pressures firms to secure better prices from other advanced nations, effectively using investment withdrawals as leverage against the U.K. The trend also signals a broader strategic capital reallocation towards the U.S., which is actively incentivizing domestic investment from giants like Novartis and Sanofi. The U.K. is described as the "first practical case" of this capital flight, underscoring its declining attractiveness, as evidenced by its fall in the pharmaceutical foreign direct investment (FDI) ranking from second in 2017 to seventh in 2023.

Key Decisions for Investors

• Investors in AstraZeneca (AZN), Merck (MRK), and Eli Lilly (LLY) should view the paused U.K. investments as a near-term headline risk but primarily as a negotiation tactic; a resolution in U.K. pricing talks could reverse this negative sentiment and the investment decisions.
• Consider overweighting pharmaceutical companies with significant U.S. R&D and manufacturing exposure, as the trend of capital reallocation, demonstrated by Novartis and Sanofi, favors the U.S. market at the expense of European geographies facing pricing and investment headwinds.
• Monitor the U.K. government's policy response to this pressure, as any meaningful concessions to improve the life sciences environment could present a tactical buying opportunity in U.K.-exposed pharmaceutical and biotech assets currently facing uncertainty.